Quick Answer
Silexion Therapeutics Corp reported Diluted EPS of $8.96 per share for fiscal year 2025.
Silexion Therapeutics Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $8.96 | -97.7% |
| 2024 | $394.94 | +792.9% |
| 2023 | $44.23 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.88 | -98.9% | -33.3% |
| June 30, 2025 | $4.32 | -97.8% | +1561.5% |
| March 31, 2025 | $0.26 | -97.9% | -99.9% |
| September 30, 2024 | $274.25 | +35060.3% | +38.7% |
| June 30, 2024 | $197.80 | +2924.5% | +1509.4% |
| March 31, 2024 | $12.29 | — | +1475.6% |
| September 30, 2023 | $0.78 | — | -88.1% |
| June 30, 2023 | $6.54 | — | — |
- Silexion Therapeutics Corp showed a decrease of -97.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Silexion Therapeutics Corp’s diluted eps has declined by 79.7% (from $44.23 per share to $8.96 per share).
- The most recent figure is from Silexion Therapeutics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: